IONIS PHARMACEUTICAL

IONS
Delayed Quote. Delayed  - 09/27 04:00:00 pm
35.87USD -0.91%
Business Summary
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Other Biotechnology & Medical Research
Ionis Pharmaceuticals, Inc. is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company's segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners. The Akcea Therapeutics segment includes the operations of the Company's subsidiary, Akcea Therapeutics, Inc. (Akcea Therapeutics). Akcea Therapeutics is focused on developing and commercializing volanesorsen and other clinical-stage drugs for serious cardiometabolic diseases caused by lipid disorders. The Company is developing volanesorsen to treat two severe and rare, genetically defined diseases, familial chylomicronemia (FCS) and familial partial lipodystrophy (FPL). The Company offers SPINRAZA, a Generation 2.0+ antisense drug.

Number of employees : 757 people.
Sales per Business
20192020
Ionis Core858.6576.5%622.9485.4%
Akcea Therapeutics488.5443.5%152.3220.9%
USD in Million
Sales per region
20192020
United States1 122.60100%729.26100%
USD in Million
Managers
Name Title
Brett P. Monia Chief Executive Officer & Director
Elizabeth L. Hougen Chief Financial Officer & Executive VP-Finance
Joseph Loscalzo Chairman
C. Frank Bennett Chief Scientific Officer & Executive VP
Sanjay Bhanot Chief Medical Officer
Joel Ekstorm Vice President-Information Technology
Eugene Schneider Chief Clinical Development Officer & Executive VP
Joel Edwards Vice President-Corporate & Commercial Operations
Patrick R. O'Neil Secretary, Chief Compliance Officer & EVP-Legal
Joseph H. Wender Lead Independent Director
Shareholders
Name Equities %
Fidelity Management & Research Co. LLC 21,144,455 15.0%
The Vanguard Group, Inc. 12,448,018 8.82%
T. Rowe Price Associates, Inc. (Investment Management) 12,258,827 8.69%
Bellevue Asset Management AG 9,930,245 7.04%
ARK Investment Management LLC 8,907,733 6.31%
ClearBridge Investments LLC 6,815,601 4.83%
Columbia Wanger Asset Management LLC 5,083,000 3.60%
BlackRock Fund Advisors 3,417,436 2.42%
SSgA Funds Management, Inc. 3,230,951 2.29%
OppenheimerFunds, Inc. 2,027,449 1.44%
Company contact information
Ionis Pharmaceuticals, Inc.
2855 Gazelle Court
Carlsbad, CA 92010

Phone : +1.760.931.9200
Fax : +1.760.918.3592
Web : http://www.ionispharm.com
Sector Other Biotechnology & Medical Research
1st jan.Capi. (M$)
IONIS PHARMACEUTICALS, INC.-36.56%5 110
MODERNA, INC.291.35%173 624
LONZA GROUP AG26.86%59 611
IQVIA HOLDINGS INC.38.49%50 128
CELLTRION, INC.-25.49%31 745
SEAGEN INC.-7.21%29 353
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.73.08%23 097
ICON PUBLIC LIMITED COMPANY39.09%22 554
ALNYLAM PHARMACEUTICALS, INC.49.15%22 272
PHARMARON BEIJING CO., LTD.78.56%22 122
BIO-TECHNE CORPORATION61.06%21 145
HANGZHOU TIGERMED CONSULTING CO., LTD6.57%19 364
NOVAVAX, INC.107.19%18 484
PPD, INC.36.65%16 459
INCYTE CORPORATION-20.67%15 238
QIAGEN N.V.-0.40%12 284
BACHEM HOLDING AG91.40%11 979
PRA HEALTH SCIENCES, INC.0.00%10 965
INTELLIA THERAPEUTICS, INC.171.29%10 960
SYNEOS HEALTH, INC.38.65%9 966
CRISPR THERAPEUTICS AG-23.96%8 872
Brand Portfolio
» More brands of Ionis Pharmaceuticals, Inc.